Lilly Acquires 4E Therapeutics to Fast-Track Non-Opioid Pain Therapy
Eli Lilly has acquired Austin-based 4E Therapeutics to advance a non-opioid pain program that targets the MNK-eIF4E signaling pathway in peripheral sensory neurons. 4E’s lead MNK inhibitor 4ET1103 showed favorable Phase 1 safety, and Lilly will integrate 4E’s neuroscience capabilities into its broader pain portfolio. Terms were not disclosed.